Ybj. Aldenhoff et al., Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin (R)) coating on its lumenal surface, J BIOMED MR, 54(2), 2001, pp. 224-233
A porous polyurethane vascular prosthesis with an internal diameter of 5 mm
was studied. The graft carries a coating of immobilized dipyridamole (Pers
antin(R)) on the surface of its lumen. Dipyridamole is a potent nontoxic in
hibitor of platelet activation/aggregation, and also a strong inhibitor of
vascular smooth muscle cell proliferation. The polyurethane material is als
o known as Chronoflex(R), and already finds use as a vascular access graft.
The coated vascular graft was studied in vitro (hemocompatibility, interac
tion with blood platelets and cultured endothelial cells), as well as in tw
o established in vivo models. In the first in vivo study, coated grafts wer
e implanted in goats, as a bypass of the carotid artery (four animals, eigh
t grafts, length of the graft was approximately 12 cm). Four uncoated graft
s were used as controls in otherwise identical experiments. in the second i
n vivo experiment, eight sheep were used. Each animal received one coated a
nd one uncoated prosthesis as an interposition graft in the carotid artery
(length of the graft was 4 cm). The in vitro experiments revealed that the
dipyridamole coating has three beneficial effects: reduced thrombogenicity,
reduced adherence of blood platelets, and accommodation of a confluent mon
olayer of endothelial cells. The goat experiments showed patency of the coa
ted grafts in three of the eight cases. The sheep experiments were not usef
ul for the evaluation of the dipyridamole coating because deterioration of
the polyurethane material was observed. The in vivo results indicate that t
he dipyridamole coating may positively influence the patency rate, probably
because the coating promotes the growth of an endothelial cell lining. The
sheep data show, however, that the limited stability of the Chronoflex(R)
material precludes its issue for the construction of permanent small-bore v
ascular grafts. (C) 2000 John Wiley & Sons, Inc.